22.12.2021 13:37:10
|
Alnylam Pharma Files Clinical Trial Authorization Application For ALN-APP In The UK
(RTTNews) - Alnylam Pharmaceuticals, Inc. (ALNY) has submitted a Clinical Trial Authorization application to The Medicines and Healthcare Products Regulatory Agency in the United Kingdom to begin a phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein for the treatment of Alzheimer's disease and cerebral amyloid angiopathy.
Alnylam Pharmaceuticals plans to begin the phase 1 study in patients with early-onset Alzheimer's disease in early 2022, upon obtaining MHRA approval, and expects to report initial human data at or around year-end 2022.
ALN-APP, the first-ever RNAi therapeutic targeting CNS diseases, is being advanced in partnership with Regeneron as part of Alnylam Pharma's 2019 agreement.
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Alnylam Pharmaceuticals Inc.mehr Nachrichten
12.02.25 |
Ausblick: Alnylam Pharmaceuticals informiert über die jüngsten Quartalsergebnisse (finanzen.net) | |
30.10.24 |
Ausblick: Alnylam Pharmaceuticals stellt Quartalsergebnis zum abgelaufenen Jahresviertel vor (finanzen.net) |
Analysen zu Alnylam Pharmaceuticals Inc.mehr Analysen
Aktien in diesem Artikel
Alnylam Pharmaceuticals Inc. | 250,70 | -0,44% |
|
Regeneron Pharmaceuticals Inc. | 642,40 | 0,09% |
|